iRadimed (FRA:46K) Moat Score: 5/10 (As of Jul. 11, 2026)


FRA:46K iRadimed Corp FRA:46K
87 GF Score
Price €84.50
GF Value €56.24
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is iRadimed Moat Score?

iRadimed FRA:46K +1.81% 87 Moat Score is 5 as of Jul. 11, 2026. GuruFocus rates FRA:46K with a GF Score™ of 87/100 and a GF Value™ of €56.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 843 Medical Devices & Instruments companies, iRadimed ranks better than 91.22% on this metric.

iRadimed has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

iRadimed has Narrow Moat: iRadimed Corp has a solid narrow moat with its niche focus on MRI-compatible medical devices, creating switching costs and some brand loyalty. However, its market share and scale are not sufficient to classify it as a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes iRadimed might have Narrow Moat - Solid narrow moat.

iRadimed  (FRA:46K) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

iRadimed Moat Score Related Terms

FRA:46K vs AVNS, LMRI, AORT: Moat Score Comparison

For the Medical Devices subindustry, iRadimed's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iRadimed Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Moat Score distribution charts can be found below:

* The bar in red indicates where iRadimed's Moat Score falls into.


FRA:46K
87GF Score
iRadimed Corp FRA:46K
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
iRadimed (FRA:46K) has a Moat Score of 5 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, iRadimed ranks #74 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is iRadimed's Moat Score too high?
iRadimed's current Moat Score is 5. Based on the distribution chart, iRadimed ranks #74 out of 843 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRadimed has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Moat Score compare to AVNS and LMRI?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #74 out of 843 companies for Moat Score. This places iRadimed in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. iRadimed's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.24, compared to a current price of €84.50 — trading 50.2% above its estimated fair value. The current Moat Score is 5. iRadimed's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Moat Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRadimed (FRA:46K) Overvalued in 2026?

Based on GuruFocus' analysis, iRadimed stock appears to be overvalued. The current stock price of €84.50 is trading 50.2% above its estimated GF Value™ of €56.24. GuruFocus considers iRadimed to be Significantly Overvalued.

Key valuation signals for FRA:46K:

  • Moat Score: 5
  • GF Value™: €56.24 vs. price of €84.50 (50.2% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iRadimed Business Description

Other Exchanges IRMD:USA
Address 12705 Ingenuity Drive, Orlando, FL, USA, 32826
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
87GF Score

Get the complete analysis for FRA:46K

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€84.50
Price
€56.24
GF Value